X
All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE).
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Dupilumab
Therapeutic Area: Gastroenterology Product Name: Dupixent
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
Dupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13. Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary Disease .
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
